---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-25-000010"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-26T23:57:52.245610+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# iBio Q2 FY2025 net loss $4.4M; cash $7.2M; advances pipeline

## Summary
- Revenue $0.2M; net loss $4.4M ($0.48/shr) vs $4.5M ($2.42/shr) prior year.
- Cash & equivalents $7.2M as of Dec 31, 2024, including $0.2M restricted.
- Discovered novel Activin E antibody; in-licensed anti-myostatin IBIO-600 in Jan 2025.
- Initiated bispecific myostatin/activin A program; plans clinical investigation in 2026.
- Board added David Arkowitz and António Parada; insider private placement closed Jan 2025.

## SEC filing metadata
- accession: 0001420720-25-000010
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000010/0001420720-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000010/ibio-20250210x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-25-000010
- JSON: https://secwatch.observer/filing/0001420720-25-000010.json
- Plain text: https://secwatch.observer/filing/0001420720-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.